Research programme: type 2 diabetes mellitus therapy - deCODE genetics

Drug Profile

Research programme: type 2 diabetes mellitus therapy - deCODE genetics

Latest Information Update: 30 Jan 2013

Price : $50

At a glance

  • Originator deCODE genetics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 08 Mar 2006 deCODE reported the discovery of the genetic risk factor for type 2 diabetes in the gene on chromosome 10 encoding transcription factor 7-like 2 (TCF7L2)
  • 23 Aug 2005 This programme is still in active development
  • 14 Aug 2003 deCode genetics has announced a milestone in their joint programme with Roche Diagnostics in type 2 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top